目的研究促凋亡基因PDCD5和Caspase-3 mRNA在多发性骨髓瘤(MM)中的表达,并讨论其在MM的发生、发展及预后中的意义。方法从收集40例MM患者及10例正常对照的骨髓标本中取骨髓单个核细胞(BM-MCs),采用实时荧光定量PCR(Real ti me PCR)的方...目的研究促凋亡基因PDCD5和Caspase-3 mRNA在多发性骨髓瘤(MM)中的表达,并讨论其在MM的发生、发展及预后中的意义。方法从收集40例MM患者及10例正常对照的骨髓标本中取骨髓单个核细胞(BM-MCs),采用实时荧光定量PCR(Real ti me PCR)的方法检测BMMCs中PDCD5和Caspase-3 mRNA的表达,同时收取血浆以检测β2微球蛋白(β2-MG)分泌水平,Durie-Sal mon(D-S)分期标准对MM患者进行临床分期。结果与对照组比较,PDCD5和Caspase-3 mRNA在MM组中表达明显减低(P<0.05),差异有统计学意义;复发/难治组患者PDCD5和Caspase-3 mRNA的表达仍保持较低水平;初发组与复发/难治组之间表达差异无统计学意义。PD-CD5和Caspase-3 mRNA表达与患者病程D-S分期和β2-MG(≥或<4.0 g/L)水平有负相关性(r=-0.86,P<0.05)。结论MM患者PDCD5和Caspase-3 mRNA表达水平降低,提示PDCD5和Caspase-3可能参与MM的发生发展,可能作为评判MM患者预后的新指标。展开更多
Objective To evaluate the efficacy and safety of bendamustine combined with pomalidomide and dexamethasone(BPD regimen)in the treatment of relapsed multiple myeloma(MM)with extramedullary disease.Methods This open,sin...Objective To evaluate the efficacy and safety of bendamustine combined with pomalidomide and dexamethasone(BPD regimen)in the treatment of relapsed multiple myeloma(MM)with extramedullary disease.Methods This open,single-arm,multicenter prospective cohort study included 30 relapsed MM patients with extramedullary disease diagnosed in seven hospitals,including Qingdao Municipal Hospital.展开更多
文摘Objective To evaluate the efficacy and safety of bendamustine combined with pomalidomide and dexamethasone(BPD regimen)in the treatment of relapsed multiple myeloma(MM)with extramedullary disease.Methods This open,single-arm,multicenter prospective cohort study included 30 relapsed MM patients with extramedullary disease diagnosed in seven hospitals,including Qingdao Municipal Hospital.
